Back to top
more

Assertio (ASRT)

(Delayed Data from NSDQ)

$0.91 USD

0.91
1,100,484

+0.08 (10.26%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $0.91 0.00 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why

by Zacks Equity Research

Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.

Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO

by Zacks Equity Research

Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.

Sushmita Sarker headshot

Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?

by Sushmita Sarker

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Assertio (ASRT) Q2 Earnings Miss Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -7.14% and 3.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 50% and 3.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aquestive (AQST) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.

Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -153.85% and 12.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Assertio (ASRT) closed at $5.08, marking a +1.6% move from the previous day.

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Therapeutics' (ASRT) Q1 earnings call, investors will likely focus on the sales performance of its rheumatology, pain and inflammation medicines.

Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know

by Zacks Equity Research

Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Assertio (ASRT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed the most recent trading day at $6.01, moving +1.01% from the previous trading session.

Assertio (ASRT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Assertio (ASRT) closed at $6.30, marking a +0.64% move from the previous day.

Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.

Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed at $5.78 in the latest trading session, marking a -0.86% move from the prior day.

Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.

Assertio (ASRT) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 482.61% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 16.48% and 46.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Alaunos (TCRT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings.

Assertio Holdings, Inc. (ASRT) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Cooper Companies (COO) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

The Cooper Companies (COO) delivered earnings and revenue surprises of 9.02% and 2.93%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Earnings Season Could Be Great for Assertio (ASRT)

by Zacks Equity Research

Assertio (ASRT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Assertio (ASRT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Assertio (ASRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.